Semax vs Trazodone
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both Semax and Trazodone can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Semax Trazodone
Weight 813.93 Da 371.86 Da
Half-life 0.5-2 hours ~5-9 hours
Chain 7 amino acids —
Type ACTH(4-10) synthetic analog Triazolopyridine derivative (C19H22ClN5O)
Key Benefits
Semax
01 Rapid brain delivery via intranasal route
02 Rapidly increases BDNF levels
03 Extensive clinical research in Russia
04 Easy self-administration
05 Modulates dopamine and serotonin systems
06 Neuroprotective effects
Trazodone
01 Effective sleep aid that improves sleep onset and sleep maintenance without the dependence risk of benzodiazepines
02 Enhances slow-wave (deep) sleep, which is critical for physical recovery and growth hormone release
03 Non-habit-forming with no significant tolerance development, even with long-term use
04 Widely used and well-tolerated solution for trenbolone-induced and steroid-related insomnia
05 Does not suppress REM sleep the way many other sleep medications do
06 Inexpensive, widely available as a generic, and has decades of safety data
Dosing Protocols
Semax
300-600mcg per dose (up to 1000mcg for intensive use) / 1-2x daily (morning recommended for cognitive boost)
Research protocol 500-750mcg 1x daily
Intensive protocol 750-1000mcg 1-2x daily
Trazodone
25-100 mg at bedtime (sleep) / Once daily at bedtime
Side Effects
Semax
Mild nasal discomfort (nasal route)
Possible nasal sensation upon administration
Trazodone
Morning drowsiness or grogginess (dose-dependent, more common above 50 mg)
Dry mouth
Dizziness or lightheadedness, particularly upon standing (orthostatic hypotension)
Headache
Nausea (reduced by taking with food)
Blurred vision
Contraindications
Pregnancy or breastfeeding
Known peptide allergies
Do not exceed 4-week continuous use without medical supervision
Known hypersensitivity to trazodone
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
History of priapism or conditions predisposing to priapism (e.g., sickle cell disease, multiple myeloma, leukemia)
Severe hepatic impairment (dose adjustment required in moderate impairment)
Recent myocardial infarction or unstable cardiac conditions
Pregnancy, particularly first trimester (Category C; limited human data)
Research Evidence
Semax Trazodone
Status Well Studied FDA Approved
References 5 studies 4 studies
Latest 2025 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.